We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Janus kinase inhibitors for the treatment of atopic dermatitis: Real‐life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.
- Authors
Reguiai, Z.; Becherel, P. A.; Fougerousse, A. C.; Chaby, G.; Perrot, J. L.; Begon, E.; Jacobzone‐Lévêque, C.; Boulard, C.; Badaoui, A.; Poreaux, C.; David, L.; Quiles‐Tsimaratos, N.; Lons‐Danic, D.; Fite, C.; Liegeon, A.‐L.; Patchinsky, A.; Parier, J.; Garcia, C.; Estève, E.; Mohty, R.
- Abstract
Pharmacovigilance Risk Assessment Committee recommendations were essentially based on RA data, but AD patients are generally younger and not overweight. At visit 1, corresponding to JAKi initiation, patient and AD characteristics were recorded. Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.
- Subjects
ATOPIC dermatitis; KINASE inhibitors; HERPES simplex; RISK assessment
- Publication
Journal of the European Academy of Dermatology & Venereology, 2023, Vol 37, Issue 11, pe1307
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.19302